PURPOSE: The aim of our study was to perform the final analysis of acute toxicity and quality of life data obtained from 221 consecutive patients who suffered from intermediate-to-high risk prostate cancer. METHODS: In this trial, 221 patients were randomized to receive either hypofractionated (63 Gy in 20 fractions, 4 fractions/week) or conventionally fractionated (76 Gy in 38 fractions, 5 fractions/week) radiotherapy to the prostate and seminal vesicles. Elective pelvic lymph node irradiation with 46 Gy in 23 fractions sequentially and 44 Gy in 20 fractions simultaneously was also applied. RESULTS: There was no statistically significant difference in acute GU and GI toxicity in men treated with hypofractionated (SIB) (Arm 2) in comparison with patients who had conventional fractionation (Arm 1) radiation therapy. Multivariate analysis using logistic regression showed statistical significant association between acute GU ≥ 1 and PTV(LN) (p = 0.008) only. We found out that clinically relevant decrease (CRD) was significantly higher only in the urinary domain of Arm 1 at month 3 (p = 0.02). CONCLUSION: Our study demonstrated that hypofractionated radiotherapy was associated with a small but insignificant increase of acute toxicity. The reduction of overall treatment time has no significant influence on patients' QOL in any domain.
PURPOSE: The aim of our study was to perform the final analysis of acute toxicity and quality of life data obtained from 221 consecutive patients who suffered from intermediate-to-high risk prostate cancer. METHODS: In this trial, 221 patients were randomized to receive either hypofractionated (63 Gy in 20 fractions, 4 fractions/week) or conventionally fractionated (76 Gy in 38 fractions, 5 fractions/week) radiotherapy to the prostate and seminal vesicles. Elective pelvic lymph node irradiation with 46 Gy in 23 fractions sequentially and 44 Gy in 20 fractions simultaneously was also applied. RESULTS: There was no statistically significant difference in acute GU and GI toxicity in men treated with hypofractionated (SIB) (Arm 2) in comparison with patients who had conventional fractionation (Arm 1) radiation therapy. Multivariate analysis using logistic regression showed statistical significant association between acute GU ≥ 1 and PTV(LN) (p = 0.008) only. We found out that clinically relevant decrease (CRD) was significantly higher only in the urinary domain of Arm 1 at month 3 (p = 0.02). CONCLUSION: Our study demonstrated that hypofractionated radiotherapy was associated with a small but insignificant increase of acute toxicity. The reduction of overall treatment time has no significant influence on patients' QOL in any domain.
Entities:
Keywords:
Acute toxicity; Hypofractionation; Prostate cancer; Quality of life; Radiotherapy
Authors: David Dearnaley; Isabel Syndikus; Georges Sumo; Margaret Bidmead; David Bloomfield; Catharine Clark; Annie Gao; Shama Hassan; Alan Horwich; Robert Huddart; Vincent Khoo; Peter Kirkbride; Helen Mayles; Philip Mayles; Olivia Naismith; Chris Parker; Helen Patterson; Martin Russell; Christopher Scrase; Chris South; John Staffurth; Emma Hall Journal: Lancet Oncol Date: 2011-12-12 Impact factor: 41.316
Authors: Alan Pollack; Alexandra L Hanlon; Eric M Horwitz; Steven J Feigenberg; Andre A Konski; Benjamin Movsas; Richard E Greenberg; Robert G Uzzo; C-M Charlie Ma; Shawn W McNeeley; Mark K Buyyounouski; Robert A Price Journal: Int J Radiat Oncol Biol Phys Date: 2005-10-19 Impact factor: 7.038
Authors: Michael Pinkawa; Marc D Piroth; Richard Holy; Karin Fischedick; Jens Klotz; Dalma Székely-Orbán; Michael J Eble Journal: Int J Radiat Oncol Biol Phys Date: 2010-09-09 Impact factor: 7.038
Authors: M J Zelefsky; Z Fuks; L Happersett; H J Lee; C C Ling; C M Burman; M Hunt; T Wolfe; E S Venkatraman; A Jackson; M Skwarchuk; S A Leibel Journal: Radiother Oncol Date: 2000-06 Impact factor: 6.280
Authors: Alan Pollack; Gail Walker; Eric M Horwitz; Robert Price; Steven Feigenberg; Andre A Konski; Radka Stoyanova; Benjamin Movsas; Richard E Greenberg; Robert G Uzzo; Charlie Ma; Mark K Buyyounouski Journal: J Clin Oncol Date: 2013-10-07 Impact factor: 44.544
Authors: Darius Norkus; Agata Karklelyte; Benedikt Engels; Harijati Versmessen; Romas Griskevicius; Mark De Ridder; Guy Storme; Eduardas Aleknavicius; Ernestas Janulionis; Konstantinas Povilas Valuckas Journal: Radiat Oncol Date: 2013-09-04 Impact factor: 3.481
Authors: Dalia Ahmad Khalil; Danny Jazmati; Dirk Geismar; Jörg Wulff; Christian Bäumer; Paul Heinz Kramer; Theresa Steinmeier; Stefanie Schulze Schleitthoff; Sandija Plaude; Martin Bischoff; Stephan Tschirdewahn; Boris Hadaschik; Beate Timmermann Journal: Radiat Oncol Date: 2022-04-01 Impact factor: 3.481